Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis Clinical Trial

— SPRING  

Official title:

A 12-month, Prospective, Multi-center Post-authorization Commitment (PAC) Study Monitoring Safety in Adult Patients With Relapsing-remitting Multiple Sclerosis Newly Initiated on Gilenya (Fingolimod) in Taiwan (SPRING)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04480853
• Other study ID #: CFTY720DTW03
• Status: Recruiting
• Phase: Phase 4
• Start date: October 12, 2020
• Est. completion date: January 27, 2026

Study information

• Verified date: May 2024
• Source: Novartis
• Contact: Novartis Pharmaceuticals
• Phone: +41613241111
• Email: novartis.email[@]novartis.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to describe the safety profile of fingolimod in the Taiwanese multiple sclerosis population. This study aims to collect the safety data in patients newly initiated on fingolimod for one year.

Description:

This is a 12-month, prospective, interventional, multi-center study to monitor safety in adult patients with relapsing-remitting multiple sclerosis (RRMS) in Taiwan who based on local practice are newly starting fingolimod at the time of study entry.

Thirty-four patients will be included in this study in line with the study inclusion and exclusion criteria. After entering this study, the participants will continue to be treated for MS based on local practice. The patient will be taking fingolimod 0.5mg per day. Protocol-mandated procedures and visits for safety data collection will be conducted in addition to the required examinations according to the clinical practice.

If a patient experienced an interruption of fingolimod treatment that requires a re-evaluation of FDO, the patient will be discontinued from the study. If the treatment interruption does not require a FDO when re-starting fingolimod, the patient can continue to participate in this study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 27, 2026
• Est. primary completion date: January 27, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

-Patients with relapsing-remitting multiple sclerosis that are fingolimod treatment naive at the time of study entry and are newly starting fingolimod based on physician judgement and according to Taiwan's fingolimod package insert (version TWI-090420)

Exclusion Criteria:

• Patients with the diagnosis of neuromyelitis optica.

• Patients who are being treated with any investigational drug at the time of study entry.

• In the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization or Class III/IV heart failure

• A history or presence of Mobitz Type II second-degree or third-degree atrioventricular block or sick sinus syndrome, unless patient has a functioning pacemaker

• A baseline QTc interval = 500 msec

• Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs

• Patient with known immune deficiency, increased risk of opportunistic infection, severe active infection or chronic active infection.

• Patients with severe active malignancies, except for basal cell epithelioma

• Patients with severe hepatic insufficiency

• Pregnant or nursing (lactating) women or women of childbearing potential unless on contraception

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Sclerosis

Intervention

Drug:
• Fingolimod
Fingolimod 0.5 mg QD, oral

Locations

Country	Name	City	State
Taiwan	Novartis Investigative Site	Kaoshiung
Taiwan	Novartis Investigative Site	Taichung
Taiwan	Novartis Investigative Site	Tainan
Taiwan	Novartis Investigative Site	Taipei
Taiwan	Novartis Investigative Site	Taipei
Taiwan	Novartis Investigative Site	Taoyuan

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Adverse Events of Special Interest(AESI)	The adverse events of special interest (AESI) include bradycardia and Grade 2 or higher AV block during First Dose Observation.	First Dose Observation on the first day of taking findolimod
Primary	Number of Adverse Events of Special Interest (AESI)	The adverse events of special interest (AESI) include macular edema, abnormal liver function(ALT, AST or GGT > 5x upper normal limit), and severe lymphocytopenia(lymphocyte < 200 cells/µL).	Baseline up to 12 months
Secondary	Annualized relapse reate (ARR)	The ARR will be calculated as total number of relapses experienced divided by total number of days of follow-up, and the ratio multiplied by 365. For patients withdraw from the study or switch to an alternative MS therapy prior to 12 month, the total number of days in study is defined as the number of days from baseline to the last date in study.	Baseline up to 12 months
Secondary	Change from baseline of Pulse (beats/min)	Pulse (beats/min - bpm) data will be summarized as descriptive statistics for change from baseline value (both for the period 6-hours post first dose and for further visit assessments). The frequency and percentage of notable vital sign abnormalities will be summarized. Notable criteria for pulse is > 120bpm or Increase of =15 bpm from baseline Or < 50bpm or Decrease of =15 bpm from baseline	Baseline up to 12 months
Secondary	Change from baseline of blood pressure (mmHg)	Blood pressure(BP)(mmHg) data will be summarized as descriptive statistics for change from baseline value (both for the period 6-hours post first dose and for further visit assessments). The frequency and percentage of notable vital sign abnormalities will be summarized. Notable criteria for systolic BP is =160 mm Hg or Increase of =20 mm Hg from baseline Or = 90 mm Hg or Decrease of = 20 mm Hg from baseline. Notable criteria for diastolic BP is = 100 mmHg or Increase of = 15 mm Hg from baseline Or = 50 mmHg or Decrease of = 15 mm Hg from baseline.	Baseline up to 12 months